Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15691MR)

This product GTTS-WQ15691MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Macular edema following Central Retinal Vein Occlusion (CRVO), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15691MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5090MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ12235MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ7807MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ7417MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ2865MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ12211MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ13367MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ13998MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW